6134-54-9

Basic information

• Product Name: 5-Bromoindane
• Synonyms: 5-bromoindane;5-Bromo-indan;1H-INDENE, 5-BROMO-2,3-DIHYDRO
• CAS NO: 6134-54-9
• Molecular Formula: C₉H₉Br
• Molecular Weight: 197.07
• Mol File: 6134-54-9.mol
• Article Data: 12

Chemical Properties

• Melting Point: -7 °C
• Boiling Point: 236.9°C at 760 mmHg
• Flash Point: 99.8°C
• Appearance: /
• Density: 1.462g/cm³
• Vapor Pressure: 0.071mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-Bromoindane(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromoindane(6134-54-9)
• EPA Substance Registry System: 5-Bromoindane(6134-54-9)

Safety Data

• Hazardous Substances Data: 6134-54-9(Hazardous Substances Data)

Usage

General Description

5-Bromoindane, also known as 1-(5-Bromo-1H-inden-3-yl)ethanone, is a chemical compound with the molecular formula C10H9BrO. It is a brominated indane derivative that is commonly used in the field of organic synthesis and medicinal chemistry. 5-Bromoindane has been studied for its potential therapeutic effects in the treatment of various neurological and psychiatric disorders, including depression, anxiety, and neurodegenerative diseases. It has also been investigated for its potential as a dopaminergic agent and has shown promise in preclinical studies. Additionally, 5-Bromoindane has been used as a reagent in the synthesis of other organic compounds and as a precursor in the preparation of pharmaceuticals. However, its safety and potential toxicological effects in humans have not been fully established, and further research is needed to evaluate its potential applications and risks.

InChI:InChI=1/C9H9Br/c10-9-5-4-7-2-1-3-8(7)6-9/h4-6H,1-3H2

Upstream product

• 42287-90-1 3-(3-bromophenyl)propanoic acid 
• 17680-55-6 7-bromo-1,2,3,4-tetrahydroisoquinoline 
• 617-86-7 triethylsilane 
• 34598-49-7 5-Bromo-1-indanone 
• 496-11-7 INDANE 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 
• 24425-40-9 indan-5-amine 

Downstream Products

• 1332332-41-8 5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-4-[4-(2,3-dihydro-1H-inden-5-yl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 445303-13-9 2-(2,3-dihydro-1H-inden-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 81614-72-4 5-(2,4-difluorophenoxy)-6-nitroindan 
• 75370-30-8 N-(6-Phenoxy-5-indanyl)-methansulfonamid 
• 75369-87-8 5-(4-chlorophenoxy)-6-nitroindan 
• 75369-89-0 5-(4-Fluoro-phenoxy)-6-nitro-indan 
• 75369-93-6 5-(3-Chloro-phenoxy)-6-nitro-indan 
• 75369-99-2 5-(3-Fluoro-phenoxy)-6-nitro-indan 
• 81614-79-1 6-(2,4-difluorophenoxy)-5-indanylamine 
• 75370-08-0 6-(4-chlorophenoxy)-5-indanylamine 
• 75370-10-4 6-(4-fluorophenoxy)-5-indanylamine 
• 75370-07-9 6-Phenoxy-5-indanylamin 
• 81618-03-3 N-[6-(2,6-Difluoro-phenoxy)-indan-5-yl]-methanesulfonamide 
• 75360-54-2 N-[6-(2,4-dichlorophenoxy)-5-indanyl]methanesulfonamide 

Relevant articles and documents

INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION

Compounds of Formula (I) and methods of inhibiting the replication of viruses in a biological sample or patient, of reducing the amount of viruses in a biological sample or patient, and of treating a virus infection in a patient, comprising administering to said biological sample or patient an effective amount of a compound represented by Formula (I), a compound of Table A or B or a pharmaceutically acceptable salt thereof.

As a new polyphenylenepolymethylenepolyisocyanate deriv. SGLT2 inhibitor

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.

TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.